Bristol Myers Squibb (BMS): latest news - GoINPHARMA
Wednesday, 19 September 2018 - 12:39

Bristol Myers Squibb (BMS)

BMS’ Opdivo obtains FDA approval for SCLC

It is a great momentum for Bristol-Myers Squibb group: immunotherapy Opdivo (nivolumab) was approved by FDA last Friday for small-cell lung cancer (SCLC) in patients already treated twice, but with no therapeutic benefit. The approval reflects positive clinical results from…

Bristol-Myers Squibb’s Opdivo approved in Europe for melanoma

Bristol-Myers Squibb’s shares opened the trading day with an impressive +2% as the US-based group announced that EMA had approved Opdivo (nivolumab) for the treatment of melanoma with involvement of lymph nodes or metastatic disease (Phases III and IV). Opdivo,…

Quarter exceeding expectations for Bristol-Myers Squibb

Bristol-Myers Squibb yesterday reported its Q2 2018 financial results, which have not convinced analysts and investors, indeed shares have declined by over 1.5%, despite revenues have increased by 11% ($5.75m), with a 71% gross margin. Opdivo is still the group’s…

First colorectal-cancer immunotherapy to be approved

According to Bristol-Myers Squibb’s announcement, FDA has approved immunotherapy combination use of Opdivo (nivolumab) plus Yervoy (ipilimumab) – both property of BMS – to treat metastatic colorectal cancer after chemotherapy (fluoropyrimidine, oxaliplatin and irinotecan). As a matter of fact, this…

BMS hires banks to put French OTC division on sale (€1bn)

Reuters has reported that Bristol-Myers Squibb has hired Deutsche Bank and Jefferies to look for buyers of its French division producing and marketing OTCs, worth over €1bn. The French asset delivered sales of €425m in 2017 and has 1,500 employees….

A puzzling Bristol-Myers Squibb

US-based Bristol-Myers Squibb on Thursday reported its first-quarter results, which have raised uncertainty about the company’s actual potential. BMS generated sales of $5.19bn, that is a +5% increase over Q1 2017, below the $5.22bn expected by analysts. Revenues from Opdivo,…

Wacker acquisisce un sito per prodotti biofarmaceutici nel Lussenburgo

Bristol-Myers Squibb today reported, before Wall Street opened, detailed results from the Phase III CheckMate-227 clinical trial, testing Opdivo (nivolumab) low-dose 3 mg/kg plus Yervoy (ipilimumab) 1 mg/kg in patients with non-small cell lung cancer (NSCLC). The results show that…

Bristol-Myers Squibb enters into $3.6bn agreement with Nektar Therapeutics

Bristol-Myers Squibb is pursuing M&A again: yesterday, in the late evening, it announced an agreement with Nektar Therapeutics, expanding the existing strategic collaboration agreement signed in 2016 by the two companies for the scientific and commercial development of immunotherapy NKTR-214…

Positive financial results for BMS but shares drop due to analysts’ skepticism

Bristol-Myers Squibb’s (BMS) shares have followed today a curious trend: they have dropped 3%, although the 2017 financial results, announced today, are slightly exceeding expectations. BMS–like other US-based pharmaceutical groups–has posted negative profits (-$2.3bn), following adjustments due to the Trump…

Reversing trend: US big pharma invests in European biotech companies

The Dutch venture capital fund BioGeneration Ventures yesterday issued a release announcing that it has raised approximately €82m in funding to be invested in medical devices and diagnostics in Germany and Benelux. The main investors include US-based groups Bristol-Myers Squibb…

Positive times for Bristol-Myers Squibb

Bristol-Myers Squibb is experiencing an extremely positive phase, and investors share this view: indeed, BMS’ shares have risen over 17% in the last three months and capitalization is now $106bn, with a P/E ratio of 23. Most of the credit…

New strategic move by BMS: collaboration with Infinity Pharmaceuticals expanded

Bristol-Myers Squibb and Cambridge, US-based biotech company Infinity Pharmaceuticals announced they have expanded the cooperation agreement aimed at evaluating Infinity’s IPI-549 in combination with Opdivo (nivolumab) to include patients with triple negative breast cancer (TNBC). TNBC has shown resistance to…

Bristol-Myers Squibb acquires IFM Therapeutics

Bristol-Myers Squibb yesterday announced, after trading closed (Wall Street), that it acquired IFM Therapeutics for $300m. The agreement allows further payments up to a maximum of $1.01bn for each of the two products comprising IFM Therapeutics’ pipeline launched on the…

Bristol-Myers Squibb sold plant to Seattle Genetics for $43.3m

US-based multinational Bristol-Myers Squibb announced it sold its Monte Villa Parkway Research Center manufacturing facility in Bothell (Washington) to Seattle Genetics for $43.3m. The 51,000sft plant, opened in 2014, is one of the most technologically advanced in the whole pharmaceutical…

Opdivo better than Yervoy in treating melanoma

Bristol-Myers Squibb announced today before Wall Street opened that the Phase III CheckMate -238 clinical trial, designed to assess the efficacy of Opdivo 3 mg/kg vs Yervoy 10 mg/kg in patients with stage IIIb/c or stage IV melanoma, met its…

Immunotherapy takes risky gamble

Many analysts believe there is excessive enthusiasm in the pharmaceutical market about immunotherapies for cancer. Merck & Co. and Bristol-Myers Squibb lead the industry until now, with their respective immunotherapies Keytruda and Opdivo, both “checkpoint inhibitors”, generating together over $4bn…

BMS sells Swords production plant (Ireland) to SK Biotek

South Corea-based SK Biotek acquired the Bristol-Myers Squibb’s production plant in Swords, Ireland. The facility manufactures a wide range of drugs, the most important being Eliquis, against blood clot. SK plans to operate the plant on behalf of third parties,…

Bristol-Myers Squibb increasingly vulnerable to takeover

Bristol-Myers Squibb has been losing almost $37bn over the last 12 months, following a failed clinical trial testing Opdivo as a lung cancer treatment. This blockbuster was developed by Medarex, a company acquired in 2009 for $2.4bn, and is more…

BMS, Novartis strike partnership to assess Opdivo-Mekinist combination

Novartis and Bristol-Myers Squibb announced a collaboration to assess the safety, tolerability, and efficacy of Mekinist (trametinib) in combination with Opdivo (nivolumab) and Opdivo plus Yervoy (ipilimumab) as a potential treatment option for metastatic colorectal cancer in a certain patients…

Wall Street could soon trust Bristol-Myers Squibb again

Bristol-Myers Squibb’s shares have been losing approximately 24% from August 2016 as the clinical trial assessing Opdivo as a lung cancer treatment failed. Although many investors lost interest in BMS, there is a widespread feeling in Wall Street that its…